Int J Stomatol

Inter J Stomatol ›› 2017, Vol. 44 ›› Issue (1): 69-74.doi: 10.7518/gjkq.2017.01.013

• ·Treatment Studies • Previous Articles     Next Articles

Dosage and course of treatment—treating oral pemphigus vulgaris with systemic glucocorticoid therapy

Wang Jiongke, Zhang Xuefeng, Chen Qianming, Zeng Xin.   

  1. State Key Laboratory of Oral Diseases, Dept. of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2016-04-11 Online:2017-01-01 Published:2017-01-01

RichHTML

14

PDF (PC)

689

Abstract: Pemphigus vulgaris is a kind of auto-immune mucocutaneous blistering disease, and glucocorticoids are the most classic and common treatment for it. Research on the therapies for pemphigus vulgaris is abundant; however, most studies have focused on the classification of treatments and have failed to evaluate the initial dosage. Moreover, reports on tapering dosages and maintenance therapy are rarer. At present, foreign guidelines on methods for treating pemphigus vulgaris with systemic glucocorticoid therapy have come from dermatological experts from Japan, Europe, and Britain. We have no guideline of our own, and clinicians strongly rely on their experience alone. This paper expounds on safely and effectively using oral glucocorticoids in the treatment of pemphigus vulgaris from the perspectives of dosage and the course of treatment. This paper also attempts to present treating standards via related essays and guidelines and provides management strategies for treating pemphigus vulgaris with glucocorticoids.

Key words: pemphigus vulgaris, glucocorticoid, therapy

CLC Number: 

  • R781.5+9

TrendMD: 
[1] Groves RW. Pemphigus: a brief review[J]. Clin Med(Lond), 2009, 9(4):371-375.
[2] Guillen S, Khachemoune A. Pemphigus vulgaris: a short review for the practitioner[J]. Dermatol Nurs, 2007, 19(3):269-272.
[3] 王心声, 付萍. 天疱疮的治疗现状[J]. 皮肤病与性病, 2011, 33(1):28-30. Wang XS, Fu P. Advances in pemphigus therapy[J]. J Dermatol Venereol, 2011, 33(1):28-30.
[4] Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update[J]. Arch Dermatol, 1996, 132(2):203-212.
[5] Yeh SW, Sami N, Ahmed RA. Treatment of pemphi-gus vulgaris: current and emerging options[J]. Am J Clin Dermatol, 2005, 6(5):327-342.
[6] Bystryn JC, Rudolph JL. Pemphigus[J]. Lancet, 2005, 366(9479):61-73.
[7] Committee for Guidelines for the Management of Pemphigus Disease, Amagai M, Tanikawa A, et al. Japanese guidelines for the management of pemphi-gus[J]. J Dermatol, 2014, 41(6):471-486.
[8] Dick SE, Werth VP. Pemphigus: a treatment update [J]. Autoimmunity, 2006, 39(7):591-599.
[9] Herbst A, Bystryn JC. Patterns of remission in pem-phigus vulgaris[J]. J Am Acad Dermatol, 2000, 42 (3):422-427.
[10] Scully C, Mignogna M. Oral mucosal disease: pem-phigus[J]. Br J Oral Maxillofac Surg, 2008, 46(4): 272-277.
[11] 陈喜雪, 朱学骏. 天疱疮及大疱性类天疱疮的治疗[J]. 继续医学教育, 2006, 20(23):54-56. Chen XX, Zhu XJ. Therapy of pemphigus and bullo-us pemphigoid[J]. Contin Med Edu, 2006, 20(23): 54-56.
[12] 黄莺. 天疱疮与类天疱疮的治疗[J]. 现代临床医学, 2009, 35(5):391-392. Huang Y. Treatment of pemphigus and pemphi-goid[J]. J Modern Clin Med, 2009, 35(5):391-392.
[13] 董广英, 周威, 赵瑞芳. 小剂量皮质激素在控制天疱疮复发中的应用[J]. 实用口腔医学杂志, 2005, 21(3):386-388. Dong GY, Zhou W, Zhao RF. Recurrence control of pemophigus by corticosteroids with small dosage[J]. J Pract Stomatol, 2005, 21(3):386-388.
[14] 王顺英, 陈谦明. 口腔天疱疮治疗刍议[J]. 临床口腔医学杂志, 1992, 8(3):132-134. Wang SY, Chen QM. The treatment of oral pem-phigus[J]. J Clin Stomatol, 1992, 8(3):132-134.
[15] Nousari HC, Anhalt GJ. Pemphigus and bullous pemphigoid[J]. Lancet, 1999, 354(9179):667-672.
[16] Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment—guided by the European Dermatology Forum(EDF) in coope-ration with the European Academy of Dermatology and Venereology(EADV)[J]. J Eur Acad Dermatol Venereol, 2015, 29(3):405-414.
[17] Harman KE, Albert S, Black MM, et al. Guidelines for the management of pemphigus vulgaris[J]. Br J Dermatol, 2003, 149(5):926-937.
[18] Tóth GG, Jonkman MF. Therapy of pemphigus[J]. Clin Dermatol, 2001, 19(6):761-767.
[19] 朱学骏. 天疱疮与类天疱疮的治疗[J]. 临床皮肤科杂志, 2000, 29(6):381-382. Zhu XJ. Treatment of pemphigus and pemphigoid[J]. J Clin Dermatol, 2000, 29(6):381-382.
[20] 周曾同, 徐辉欢. 口腔天疱疮的治疗体会[J]. 中国实用口腔科杂志, 2008, 1(8):451-454.Zhou ZT, Xu HH. Treatment experience of oral pemphigus[J]. Chin J Pract Stomatol, 2008, 1(8): 451-454.
[21] 周威, 赵瑞芳. 天疱疮治疗的探讨[J]. 中华口腔医学杂志, 2005, 40(2):108-111. Zhou W, Zhao RF. The discussion of pemphigus treatment[J]. Chin J Stomatol, 2005, 40(2):108-111.
[22] 陈谦明, 曾昕. 案析口腔黏膜病学[M]. 北京: 人民卫生出版社, 2014:85-92. Chen QM, Zeng X. Case-based oral medicine[M]. Beijing: People’s Medical Publishing House, 2014: 85-92.
[1] Mao Qirong,Yin Heng,Li Jingtao. Progress in the management of marginal velopharyngeal incompetence [J]. Int J Stomatol, 2024, 51(1): 116-124.
[2] Liu Shiyi, Chen Zhong, Zhang Suxin. Progress in research into programmed death-1/programmed death-ligand 1 immunotherapy strategies in human papillomavirus-positive head and neck squamous cell carcinoma [J]. Int J Stomatol, 2024, 51(1): 21-27.
[3] He Zimu, Li Fenglan. Present application of digital oral positioning stents in radiotherapy of head and neck tumor [J]. Int J Stomatol, 2024, 51(1): 28-35.
[4] Fu Yu, He Wei, Huang Lan. Ferroptosis and its implication in oral diseases [J]. Int J Stomatol, 2024, 51(1): 36-44.
[5] Yang Dongye,Zhu Ping,Wu Shuyi. The influencing factors and clinical significance of tongue position [J]. Int J Stomatol, 2023, 50(6): 723-728.
[6] Song Wenpeng,Gong Beiwen,Li Dan,Zeng Jianyu,Qiu Lingling. Research progress on the application of mechanotherapy in orthodontic treatment [J]. Int J Stomatol, 2023, 50(5): 603-612.
[7] Fan Lin,Sun Jiang.. Application of microneedles in stomatology [J]. Int J Stomatol, 2023, 50(4): 472-478.
[8] Wang Mudan,Song Dongzhe,Huang Dingming.. Research progress on fracture resistance of endodontically treated teeth with different endodontic access cavities [J]. Int J Stomatol, 2023, 50(2): 186-194.
[9] Li Tan,Liang Xin-hua.. Role of discoidin domain receptor 1 in the regulation of malignant tumor progression and therapy [J]. Int J Stomatol, 2023, 50(2): 230-236.
[10] Yang Mingyan,Zhang Fan,Zhao Lei. Research progress on oral flora changes affecting the course of radiotherapy and chemotherapy-related oral mucositis [J]. Int J Stomatol, 2023, 50(1): 43-51.
[11] Zhou Can,Zeng Qian,Wei Xi.. Prospects for the application of concentrated growth factor in vital pulp therapy [J]. Int J Stomatol, 2022, 49(6): 684-689.
[12] Li Zhouchi,Ye Ling,Wang Chenglin.. Oral diagnosis and treatment strategies for patients with gag reflex sensitivity [J]. Int J Stomatol, 2022, 49(6): 690-698.
[13] Chen Xiaoli,Zhang Fan,Liu Chengcheng. Application progress on photobiomodulation in the prevention and treatment of oral complications after radiothe-rapy [J]. Int J Stomatol, 2022, 49(6): 707-716.
[14] Li Hongfang,Chen Zhong,Zhang Suxin.. Research progress on immune checkpoint inhibitor combined with radiotherapy in head and neck squamous cell carcinoma [J]. Int J Stomatol, 2022, 49(5): 614-620.
[15] Zhao Zhihe.. Difficulty assessment of invisible orthodontic treatment based on treatment plan and tooth movement pattern [J]. Int J Stomatol, 2022, 49(4): 373-379.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[2] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[3] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[4] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[5] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[6] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[7] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[8] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[9] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[10] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .